Prelude Therapeutics Inc (PRLD) stock
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 8/3075% above fair value
$3.52−0.26 (-6.88%)
Close on Nov 12, 2026Market cap $280.91MP/E –Yield –
Prelude Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Prelude Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -300.6%. For fiscal 2025 it was -861.3%, against -1995.9% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -861.3% | +1134.6 |
| FY2024 | Dec 31, 2024 | -1995.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -270.9% | +574.8 |
| Q1 FY2026 | Mar 31, 2026 | -309.5% | +836.3 |
| Q4 FY2025 | Dec 31, 2025 | -307.6% | – |
| Q3 FY2025 | Sep 30, 2025 | -314.1% | – |
| Q4 FY2024 | Dec 31, 2024 | -845.8% | – |
| Q3 FY2024 | Sep 30, 2024 | -1145.9% | – |
See a number that looks wrong?